Notably, ipatasertib, a selective AKT inhibitor, improved PFS in combination with paclitaxel (compared to placebo plus paclitaxel) as first-line therapy for metastatic triple-negative breast cancer in the LOTUS phase 2 trial [31]. This evidence concerns the gene AKT1 and triple-negative breast carcinoma.